Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
Qidi Wang, Lianfeng Zhang, Kazuhiko Kuwahara, Li Li, Zijie Liu, Taisheng Li, Hua Zhu, Jiangning Liu, Yanfeng Xu, Jing Xie, Hiroshi Morioka, Nobuo Sakaguchi, Chuan Qin, Gang Liu, Qidi Wang, Lianfeng Zhang, Kazuhiko Kuwahara, Li Li, Zijie Liu, Taisheng Li, Hua Zhu, Jiangning Liu, Yanfeng Xu, Jing Xie, Hiroshi Morioka, Nobuo Sakaguchi, Chuan Qin, Gang Liu
Abstract
Severe acute respiratory syndrome (SARS) is caused by a coronavirus (SARS-CoV) and has the potential to threaten global public health and socioeconomic stability. Evidence of antibody-dependent enhancement (ADE) of SARS-CoV infection in vitro and in non-human primates clouds the prospects for a safe vaccine. Using antibodies from SARS patients, we identified and characterized SARS-CoV B-cell peptide epitopes with disparate functions. In rhesus macaques, the spike glycoprotein peptides S471-503, S604-625, and S1164-1191 elicited antibodies that efficiently prevented infection in non-human primates. In contrast, peptide S597-603 induced antibodies that enhanced infection both in vitro and in non-human primates by using an epitope sequence-dependent (ESD) mechanism. This peptide exhibited a high level of serological reactivity (64%), which resulted from the additive responses of two tandem epitopes (S597-603 and S604-625) and a long-term human B-cell memory response with antisera from convalescent SARS patients. Thus, peptide-based vaccines against SARS-CoV could be engineered to avoid ADE via elimination of the S597-603 epitope. We provide herein an alternative strategy to prepare a safe and effective vaccine for ADE of viral infection by identifying and eliminating epitope sequence-dependent enhancement of viral infection.
Keywords: B-cell peptide epitope; SARS-CoV; antibody-dependent enhancement (ADE); epitope sequence-dependent (ESD) enhancement; peptide; vaccine.
Conflict of interest statement
The authors declare no competing financial interest.
Figures
References
- Hilgenfeld R.; Peiris M. (2013) From SARS to MERS: 10 years of research on highly pathogenic human coronavirus. Antiviral Res. 100 (1), 286–295. 10.1016/j.antiviral.2013.08.015.
- Drosten C.; Günther S.; Preiser W.; van der Werf S.; Brodt H. R.; et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967–1976. 10.1056/NEJMoa030747.
- Li W.; Shi Z.; Yu M.; Ren W.; Smith C.; et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676–679. 10.1126/science.1118391.
- Guan Y.; Zheng B. J.; He Y. Q.; Liu X. L.; Zhuang Z. X.; Cheung C. L.; et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276–278. 10.1126/science.1087139.
- Marra M. A.; Jones S. J.; Astell C. R.; Holt R. A.; Brooks-Wilson A.; et al. (2003) The genome sequence of the SARS-associated coronavirus. Science 300, 1399–1404. 10.1126/science.1085953.
- Rota P. A.; Oberste M. S.; Monroe S. S.; Nix W. A.; Campagnoli R.; et al. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399. 10.1126/science.1085952.
The Chinese SARS molecular epidemiology consortium
- Li W.; Moore M. J.; Vasilieva N.; Sui J.; Wong S. K.; et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454. 10.1038/nature02145.
- Jeffers S. A.; Tusell S. M.; Gillim-Ross L.; Hemmila E. M.; Achenbach J. E.; et al. (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 101, 15748–15753. 10.1073/pnas.0403812101.
- Wang B.; Chen H.; Jiang X.; Zhang M.; Wan T.; et al. (2004) Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 104, 200–206. 10.1182/blood-2003-11-4072.
- Wang Y. D.; Sin W. Y.; Xu G. B.; Yang H. H.; Wong T. Y.; et al. (2004) T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J. Virol. 78, 5612–5618. 10.1128/JVI.78.11.5612-5618.2004.
- Roberts A.; Wood J.; Subbarao K.; Ferguson M.; Wood D.; et al. (2006) Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25–26 August 2005, London, UK. Vaccine 24, 7056–7065. 10.1016/j.vaccine.2006.07.009.
- Gillim-Ross L.; Subbarao K. (2006) Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 19, 614–636. 10.1128/CMR.00005-06.
- Graham R. L.; Donaldson E. F.; Baric R. S. (2013) A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11 (12), 836–848. 10.1038/nrmicro3143.
- Yang Z. Y.; Werner H. C.; Kong W. P.; Leung K.; Traggiai E.; et al. (2005) Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. U.S.A. 102, 797–801. 10.1073/pnas.0409065102.
- Dandekar A. A.; Perlman S. (2005) Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5, 917–927. 10.1038/nri1732.
- Subbarao K.; Roberts A. (2006) Is there an ideal animal model for SARS?. Trends Microbiol. 14, 299–303. 10.1016/j.tim.2006.05.007.
- Taylor D. R. (2006) Obstacles and advances in SARS vaccine development. Vaccine 24, 863–871. 10.1016/j.vaccine.2005.08.102.
- Takada A.; Kawaoka Y. (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13, 387–398. 10.1002/rmv.405.
- Tirado S. M. C.; Yoon K. J. (2003) Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 16, 69–86. 10.1089/088282403763635465.
- Gorlani A.; Forthal D. N. (2013) Antibody-dependent enhancement and the risk of HIV infection. Curr. HIV Res. 11 (5), 421–426. 10.2174/1570162X113116660062.
- Sullivan N.; Sun Y.; Binley J.; Lee J.; Barbas C. F. 3rd; Parren P. W.; Burton D. R.; Sodroski J. (1998) Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72 (8), 6332–6338.
- Guillon C.; Schutten M.; Boers P. H.; Gruters R. A.; Osterhaus A. D. (2002) Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J. Virol. 76 (6), 2827–2834. 10.1128/JVI.76.6.2827-2834.2002.
- Gorlani A.; Forthal D. N. (2013) Antibody-dependent enhancement and the risk of HIV infection. Curr. HIV Res. 11 (5), 421–426. 10.2174/1570162X113116660062.
- Halstead S. B. (2007) Dengue. Lancet 370, 1644–1652. 10.1016/S0140-6736(07)61687-0.
- Goncalvez A. P.; Engle R. E. St; Claire M.; Purcell R. H.; Lai C. J. (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U.S.A. 104, 9422–9427. 10.1073/pnas.0703498104.
- Pierson T. C.; Xu Q.; Nelson S.; Oliphant T.; Grant E.; et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135–145. 10.1016/j.chom.2007.03.002.
- Taylor A.; Foo S. S.; Bruzzone R.; Dinh L. V.; King N. J.; Mahalingam S. (2015) Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev. 268 (1), 340–364. 10.1111/imr.12367.
- Pierson T. C.; Sánchez M. D.; Puffer B. A.; Ahmed A. A.; Geiss B. J.; Valentine L. E.; Altamura L. A.; Diamond M. S.; Doms R. W. (2006) A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346 (1), 53–65. 10.1016/j.virol.2005.10.030.
- Mehlhop E.; Ansarah-Sobrinho C.; Johnson S.; Engle M.; Fremont D. H.; Pierson T. C.; Diamond M. S. (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2 (6), 417–426. 10.1016/j.chom.2007.09.015.
- Huang K. J.; Yang Y. C.; Lin Y. S.; Huang J. H.; Lin H. S.; Yeh T. M.; Chen S. H.; Liu C. C.; Lei H. Y. (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 176, 2825–2832. 10.4049/jimmunol.176.5.2825.
- He Y. X.; Zhou Y.; Siddiqui P.; Niu J.; Jiang S. B. (2005) Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J. Clin Microbiol. 43 (8), 3718–3726. 10.1128/JCM.43.8.3718-3726.2005.
- He Y. X.; Zhou Y.; Wu H.; Kou Z. H.; Liu S. W.; Jiang S. B. (2004) Mapping of Antigenic Sites on the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome Coronavirus. J. Clin Microbiol. 42 (11), 5309–5314. 10.1128/JCM.42.11.5309-5314.2004.
- Liang Y. F.; Wan Y.; Qiu Li. W.; Zhou J.; Ni B.; Guo B.; Zou Q.; Zou L. Y.; Zhou W.; Jia Z. C.; Che X. Y.; Wu Y. Z. (2005) Comprehensive Antibody Epitope Mapping of the Nucleocapsid Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Insight into the Humoral Immunity of SARS. Clin. Chem. 51 (8), 1382–1396. 10.1373/clinchem.2005.051045.
- Hu H.; Li L.; Kao R. Y.; Kou B.; Wang Z.; et al. (2005) Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J. Comb. Chem. 7, 648–656. 10.1021/cc0500607.
- Tam J. P. (1988) Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U.S.A. 85, 5409–5413. 10.1073/pnas.85.15.5409.
- Qin C.; Wang J.; Wei Q.; She M.; Marasco W. A.; et al. (2005) An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J. Pathol. 206, 251–259. 10.1002/path.1769.
- Wong S. K.; Li W.; Moore M. J.; Choe H.; Farzan M. (2003) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279, 3197–3201. 10.1074/jbc.C300520200.
- Li W.; Zhang C.; Sui J.; Kuhn J. H.; Moore M. J.; et al. (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24, 1634–1643. 10.1038/sj.emboj.7600640.
- Xu Y.; Zhu J.; Liu Y.; Lou Z.; Yuan F.; et al. (2004) Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 43, 14064–14071. 10.1021/bi049101q.
- Xu Y.; Lou Z.; Liu Y.; Pang H.; Tien P.; et al. (2004) Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J. Biol. Chem. 279, 49414–49419. 10.1074/jbc.M408782200.
- Wang S. F.; Tseng S. P.; Yen C. H.; Yang J. Y.; Tsao C. H.; Shen C. W.; Chen K. H.; Liu F. T.; Liu W. T.; Chen Y. M.; Huang J. C. (2014) Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun. 451 (2), 208–214. 10.1016/j.bbrc.2014.07.090.
- Yip M. S.; Leung N. H.; Cheung C. Y.; Li P. H.; Lee H. H.; Daëron M.; Peiris J. S.; Bruzzone R.; Jaume M. (2014) Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol. J. 11, 82.10.1186/1743-422X-11-82.
- Jaume M.; Yip M. S.; Cheung C. Y.; Leung H. L.; Li P. H.; Kien F.; Dutry I.; Callendret B.; Escriou N.; Altmeyer R.; Nal B.; Daëron M.; Bruzzone R.; Peiris J. S. (2011) Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathwa. J. Virol. 85 (20), 10582–10597. 10.1128/JVI.00671-11.
- Dawson P. E.; Muir T. W.; Clark-Lewis I.; Kent S. B. (1994) Synthesis of proteins by native chemical ligation. Science 266, 776–779. 10.1126/science.7973629.
- Ruan Y. J.; Wei C. L.; Ee A. L.; Vega V. B.; Thoreau H.; Su S. T.; Chia J. M.; Ng P.; Chiu K. P.; Lim L.; Zhang T.; Peng C. K.; Lin E. O.; Lee N. M.; Yee S. L.; Ng L. F.; Chee R. E.; Stanton L. W.; Long P. M.; Liu E. T. (2003) Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361 (9371), 1779–1785. 10.1016/S0140-6736(03)13414-9.
- Sakaguchi N.; Kimura T.; Matsushita S.; Fujimura S.; Shibata J.; et al. (2005) Generation of High-Affinity Antibody against T Cell-Dependent Antigen in the Ganp Gene-Transgenic Mouse. J. Immunol. 174, 4485–4494. 10.4049/jimmunol.174.8.4485.
- Kuwahara K.; Yoshida M.; Kondo E.; Sakata A.; Watanabe Y.; et al. (2000) A novel nuclear phosphoprotein, GANP, is up-regulated in centrocytes of the germinal center and associated with MCM3, a protein essential for DNA replication. Blood 95, 2321–2328.
- Jönsson U. (1991) Real-time biospecific interaction analysis using surface plasmon resonance and sensor chip technology. BioTechniques 11, 620–627.
- Johnsson B.; Löfas S.; Lindquist G. (1991) Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198, 268–277. 10.1016/0003-2697(91)90424-R.
- Karlsson R.; Michaelsson A.; Mattsson L. (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods 145, 229–240. 10.1016/0022-1759(91)90331-9.
Source: PubMed